Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 2, Pages 259-273
Publisher
Rockefeller University Press
Online
2012-01-24
DOI
10.1084/jem.20111694
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias
- (2011) Chen Shochat et al. JOURNAL OF EXPERIMENTAL MEDICINE
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
- (2010) R. C. Harvey et al. BLOOD
- Cooperative Epigenetic Modulation by Cancer Amplicon Genes
- (2010) Lixin Rui et al. CANCER CELL
- A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
- (2010) Wenjun Zhou et al. CHEMISTRY & BIOLOGY
- Recent developments on JAK2 inhibitors: a patent review
- (2010) Róbert Kiss et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
- (2010) F. Baffert et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia
- (2009) T. Sanda et al. BLOOD
- Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
- (2009) L. Hertzberg et al. BLOOD
- Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
- (2009) L. J. Russell et al. BLOOD
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
- (2009) Charles G Mullighan et al. NATURE GENETICS
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling
- (2009) S Haan et al. ONCOGENE
- Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
- (2009) A. Yoda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- JAK mutations in high-risk childhood acute lymphoblastic leukemia
- (2009) C. G. Mullighan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic potential of JAK2 inhibitors
- (2009) S. Verstovsek Hematology-American Society of Hematology Education Program
- AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
- (2008) D. S. Levy et al. BLOOD
- Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
- (2008) Douglas Wardrop et al. BRITISH JOURNAL OF HAEMATOLOGY
- The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas
- (2008) Jeremy S. Abramson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
- (2008) S. A. Eccles et al. CANCER RESEARCH
- The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617Fmutation
- (2008) Taghi Manshouri et al. CANCER SCIENCE
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- (2008) T Stühmer et al. LEUKEMIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started